Profile data is unavailable for this security.
About the company
Eterna Therapeutics Inc. is a life science company committed to realizing the potential of messenger ribonucleic acid (RNA) (mRNA) cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system (collectively mRNA technology platform). Its mRNA gene-editing technology is designed to delete, insert and repair deoxyribonucleic acid (DNA) sequences in living cells, which may be useful for correcting disease-causing mutations, making cells resistant to infection and degenerative disease, modulating the expression of immunoregulatory proteins to enable the generation of durable allogeneic cell therapies, and engineering immune cells to more effectively fight cancer.
- Revenue in USD (TTM)598.00k
- Net income in USD-44.95m
- Incorporated1984
- Employees8.00
- LocationEterna Therapeutics Inc1035 Cambridge Street, Suite 18ACAMBRIDGE 02141United StatesUSA
- Phone+1 (212) 582-1199
- Fax+1 (302) 655-5049
- Websitehttps://eternatx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Athira Pharma Inc | 0.00 | -109.22m | 25.34m | 65.00 | -- | 0.4426 | -- | -- | -2.85 | -2.85 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -80.62 | -30.73 | -101.80 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
| Geovax Labs Inc | 3.09m | -24.32m | 25.48m | 17.00 | -- | 2.73 | -- | 8.24 | -9.21 | -9.21 | 0.9299 | 0.9878 | 0.2263 | -- | -- | 181,774.10 | -178.10 | -108.34 | -276.02 | -147.24 | -- | -- | -787.08 | -1,842.93 | -- | -- | 0.00 | -- | -100.00 | -- | -85.20 | -- | -- | -- |
| Equillium Inc | 45.91m | -4.62m | 25.51m | 45.00 | -- | 1.10 | -- | 0.5555 | -0.1316 | -0.1316 | 1.29 | 0.6543 | 1.02 | -- | 10.46 | 1,043,500.00 | -10.29 | -46.81 | -18.30 | -57.36 | -- | -- | -10.05 | -328.35 | -- | -- | 0.00 | -- | 128.97 | -- | 78.64 | -- | 7.48 | -- |
| ABPRO Holdings Inc | 0.00 | 4.29m | 25.57m | -- | 22.79 | 1.62 | -- | -- | 0.1396 | 0.1396 | 0.00 | 1.97 | 0.00 | -- | -- | -- | 2.48 | -- | 2.53 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 49,648.60 | -- | -- | -- |
| Marker Therapeutics Inc | 5.40m | -9.63m | 26.34m | 8.00 | -- | 3.53 | -- | 4.88 | -1.08 | -1.09 | 0.6057 | 0.837 | 0.355 | -- | 13.04 | 674,481.30 | -63.39 | -53.74 | -79.76 | -62.25 | -- | -- | -178.54 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
| Lipocine Inc | 7.92m | -4.06m | 26.74m | 17.00 | -- | 1.40 | -- | 3.38 | -0.7626 | -0.7626 | 1.48 | 3.57 | 0.3486 | -- | 119.56 | 466,054.70 | -17.85 | -39.32 | -19.49 | -45.87 | -- | -- | -51.19 | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
| DURECT Corp | 8.59m | -17.07m | 26.77m | 45.00 | -- | 22.00 | -- | 3.12 | -0.5556 | -0.5556 | 0.2813 | 0.0392 | 0.2181 | 0.7417 | 9.05 | 148,172.40 | -43.33 | -37.34 | -156.35 | -53.44 | 78.87 | 91.83 | -198.62 | -139.11 | 0.5963 | -24.30 | 0.8958 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
| Mink Therapeutics Inc | 0.00 | -13.78m | 27.28m | 31.00 | -- | -- | -- | -- | -0.3865 | -0.3865 | 0.00 | -0.4439 | 0.00 | -- | -- | 0.00 | -185.76 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
| IGC Pharma Inc | 1.18m | -12.57m | 27.30m | 67.00 | -- | 3.66 | -- | 23.08 | -0.1879 | -0.1879 | 0.0171 | 0.0963 | 0.088 | 0.2499 | 13.07 | 17,656.72 | -93.54 | -42.46 | -114.44 | -46.07 | 56.21 | 20.95 | -1,062.47 | -730.00 | 0.9779 | -- | 0.0184 | -- | 47.64 | -23.45 | -12.98 | -- | 53.72 | -- |
| Eterna Therapeutics Inc | 598.00k | -44.95m | 27.34m | 8.00 | -- | -- | -- | 45.72 | -8.31 | -8.31 | 0.1105 | -8.39 | 0.0199 | -- | 0.6093 | 74,750.00 | -149.86 | -169.05 | -222.51 | -223.00 | 72.91 | -- | -7,513.88 | -682.61 | -- | -5.43 | -- | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
| Hookipa Pharma Inc | 50.00m | -43.37m | 27.73m | 151.00 | -- | 0.3861 | -- | 0.5545 | -4.11 | -4.11 | 4.24 | 5.96 | 0.3653 | -- | 100.10 | 331,119.20 | -31.69 | -41.63 | -42.40 | -50.26 | -- | -- | -86.74 | -366.65 | -- | -- | 0.00 | -- | 41.27 | 21.41 | -25.67 | -- | 14.11 | -- |
| Longeveron Inc | 1.85m | -27.37m | 27.74m | 23.00 | -- | 1.08 | -- | 14.98 | -6.67 | -6.67 | 0.2962 | 1.73 | 0.0892 | -- | 7.78 | 80,521.74 | -86.28 | -63.15 | -102.27 | -75.68 | 73.06 | 33.70 | -967.49 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
| SAB Biotherapeutics Inc | 1.51m | -45.57m | 28.33m | 57.00 | -- | 0.7678 | -- | 18.73 | -5.84 | -5.84 | 0.1753 | 4.00 | 0.0368 | -- | 31.17 | 26,539.12 | -110.96 | -- | -142.16 | -- | -- | -- | -3,012.26 | -- | -- | -- | 0.0856 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
| RenovoRx Inc | 0.00 | -9.16m | 29.03m | 8.00 | -- | 4.11 | -- | -- | -0.572 | -0.572 | 0.00 | 0.2946 | 0.00 | -- | -- | 0.00 | -135.25 | -- | -180.14 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Eterna Therapeutics Inc's reporting currency: US Dollar USD
12.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Corient Private Wealth LLCas of 30 Sep 2024 | 262.86k | 4.86% |
| Cypress Point Wealth Management LLCas of 30 Sep 2024 | 94.38k | 1.74% |
| UBS Securities LLCas of 30 Sep 2024 | 83.62k | 1.55% |
| Naviter Wealth LLCas of 30 Sep 2024 | 78.80k | 1.46% |
| Sippican Capital Advisors LLCas of 30 Sep 2024 | 68.50k | 1.27% |
| Two Sigma Securities LLCas of 30 Sep 2024 | 32.86k | 0.61% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 26.10k | 0.48% |
| Geode Capital Management LLCas of 30 Sep 2024 | 20.44k | 0.38% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 14.92k | 0.28% |
| Avidian Wealth Enterprises LLCas of 30 Sep 2024 | 14.80k | 0.27% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
